Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers

Bookmark and Share
Published: 26 Apr 2021
Views: 315
Rating:
Save
Prof Ravi Salgia - City of Hope, Duarte, USA

Prof Ravi Salgia speaks to ecancer about the anti-tumour activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers.

Initially, he discusses the rationale of this study.

He explains that RMC-4630 is a potent, selective, orally bioavailable allosteric inhibitor of SHP2, a central node in the RAS signalling pathway.

Preclinical data have demonstrated that RMC-4630 has activity against tumours harbouring certain mutations in the RAS pathways such as KRASG12C, NF1LOF (loss of function), and BRAFClass3 (lack of/impaired kinase activity).

Prof Salgia then mentions the methodology and key results of the study.

This study showed that inhibition of pERK in patient tumours confirmed tumour intrinsic on-target activity of RMC-4630 and change of immune biomarkers in patient blood and tumours during treatment with RMC-4630 was consistent with enhancement of innate and adaptive anti-tumour immunity by RMC-4630.

In the end, Prof Salgia talks about the future of this study.